On April 9, 2025, Lucid Diagnostics Inc. entered into an underwriting agreement for a public offering of 12,500,000 shares of common stock at $1.20 per share, expecting to raise approximately $15 million. The offering includes an option for underwriters to purchase an additional 1,875,000 shares and is set to close around April 11, 2025.